Literature DB >> 12023981

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

E Joanna Baxter1, Andreas Hochhaus, Pascual Bolufer, Andreas Reiter, José M Fernandez, Leonor Senent, José Cervera, Federico Moscardo, Miguel A Sanz, Nicholas C P Cross.   

Abstract

Chronic myeloid leukaemia (CML) is characterized by the presence of the BCR-ABL fusion gene, usually in association with the t(9;22)(q34;q11) translocation. We report here the identification and cloning of a rare variant translocation, t(4;22)(q12;q11), in two patients with a CML-like myeloproliferative disease (MPD). RT-PCR indicated that both patients were negative for BCR-ABL, but FISH analysis suggested that the BCR gene was rearranged. Since other translocations in MPDs frequently involve tyrosine kinases, we designed a multiplex PCR to search for mRNA fusions between BCR and three potential partner genes at 4q12: KIT, KDR and PDGFRA. An unusual inframe BCR-PDGFRA fusion mRNA was identified in both patients, with either BCR exon 7 or exon 12 fused to short BCR intron-derived sequences, which were in turn fused to part of PDGFRA exon 12. Sequencing of the genomic breakpoint junctions showed that the chromosome 22 breakpoints fell in BCR introns whereas the chromosome 4 breakpoints were within PDGFRA exon 12. This is the first report of a fusion gene that involves PDGFRA. Our findings indicate that apparently simple cytogenetic variants of t(9;22) do not always mask a cryptic BCR-ABL fusion, even when found in association with clinical and haematological indications of CML.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023981     DOI: 10.1093/hmg/11.12.1391

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  27 in total

Review 1.  Cardiac manifestation of the hypereosinophilic syndrome: new insights.

Authors:  T Kleinfeldt; C A Nienaber; S Kische; I Akin; R G Turan; T Körber; H Schneider; H Ince
Journal:  Clin Res Cardiol       Date:  2010-03-24       Impact factor: 5.460

2.  Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

Authors:  Elizabeth H Stover; Jing Chen; Cedric Folens; Benjamin H Lee; Nicole Mentens; Peter Marynen; Ifor R Williams; D Gary Gilliland; Jan Cools
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-11       Impact factor: 11.205

3.  PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.

Authors:  Joanna J Phillips; Derick Aranda; David W Ellison; Alexander R Judkins; Sidney E Croul; Daniel J Brat; Keith L Ligon; Craig Horbinski; Sriram Venneti; Gelareh Zadeh; Mariarita Santi; Shengmei Zhou; Christina L Appin; Stefano Sioletic; Lisa M Sullivan; Maria Martinez-Lage; Aaron E Robinson; William H Yong; Timothy Cloughesy; Albert Lai; Heidi S Phillips; Roxanne Marshall; Sabine Mueller; Daphne A Haas-Kogan; Annette M Molinaro; Arie Perry
Journal:  Brain Pathol       Date:  2013-03-18       Impact factor: 6.508

Review 4.  Therapy-related acute myeloid leukemia with eosinophilia, basophilia, t(4;14)(q12;q24) and PDGFRA rearrangement: a case report and review of the literature.

Authors:  Jun Zhou; Peter Papenhausen; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Identification of cancer fusion drivers using network fusion centrality.

Authors:  Chia-Chin Wu; Kalpana Kannan; Steven Lin; Laising Yen; Aleksandar Milosavljevic
Journal:  Bioinformatics       Date:  2013-03-16       Impact factor: 6.937

6.  Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.

Authors:  Vikki Rand; Jiaqi Huang; Tim Stockwell; Steve Ferriera; Oleksandr Buzko; Samuel Levy; Dana Busam; Kelvin Li; Jennifer B Edwards; Charles Eberhart; Kathleen M Murphy; Alexia Tsiamouri; Karen Beeson; Andrew J G Simpson; J Craig Venter; Gregory J Riggins; Robert L Strausberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

7.  Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Authors:  Els Lierman; Cedric Folens; Elizabeth H Stover; Nicole Mentens; Helen Van Miegroet; Werner Scheers; Marc Boogaerts; Peter Vandenberghe; Peter Marynen; Jan Cools
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

8.  High PDGFRA expression does not serve as an effective therapeutic target in ERG-deleted B-cell precursor acute lymphoblastic leukemia.

Authors:  Isabel S Jerchel; Danai Chatzivasileiou; Alex Q Hoogkamer; Judith M Boer; H Berna Beverloo; Rob Pieters; Monique L den Boer
Journal:  Haematologica       Date:  2017-11-23       Impact factor: 9.941

9.  A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report.

Authors:  Cristiano Krings Rocha; Inka Praulich; Iris Gehrke; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Cytogenet       Date:  2011-04-01       Impact factor: 2.009

10.  Identification of leukemia-specific fusion gene transcripts with a novel oligonucleotide array.

Authors:  Sung-Min Chun; Yoo-Li Kim; Hee Baeg Choi; Yong-Taek Oh; Yoo-Jin Kim; Seok Lee; Tai-Gyu Kim; Eun Gyeong Yang; Yong-Keun Park; Dong-Wook Kim; Byoung-Don Han
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.